166 related articles for article (PubMed ID: 29088451)
21. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.
Yamasaki Y; Honkanen-Scott M; Hernandez L; Ikeda K; Barker T; Bubb MR; Narain S; Richards HB; Chan EK; Reeves WH; Satoh M
Arthritis Rheum; 2006 Sep; 54(9):3051-6. PubMed ID: 16948135
[TBL] [Abstract][Full Text] [Related]
22. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study.
Arif T; Masood Q; Singh J; Hassan I
BMC Gastroenterol; 2015 Feb; 15():24. PubMed ID: 25888470
[TBL] [Abstract][Full Text] [Related]
23. Autoantibodies in Morphea: An Update.
Khatri S; Torok KS; Mirizio E; Liu C; Astakhova K
Front Immunol; 2019; 10():1487. PubMed ID: 31354701
[TBL] [Abstract][Full Text] [Related]
24. Reactivity to anti-RNA polymerase III antibody and nailfold capillary changes in patient with generalized morphea combined with multiple autoimmune disorders.
Miyagawa F; Asada H
Eur J Dermatol; 2018 Feb; 28(1):112-113. PubMed ID: 29171400
[No Abstract] [Full Text] [Related]
25. Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis.
Molina JF; Anaya JM; Cabrera GE; Hoffman E; Espinoza LR
J Rheumatol; 1995 Mar; 22(3):557-60. PubMed ID: 7783082
[TBL] [Abstract][Full Text] [Related]
26. [Vascular lesions and fibroblast metabolism in inflammatory diseases].
Lapière CM
Phlebologie; 1987; 40(1):21-9. PubMed ID: 3575433
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous and subcutaneous inflammatory sclerosis syndromes.
Doyle JA; Connolly SM; Winkelmann RK
Arch Dermatol; 1982 Nov; 118(11):886-90. PubMed ID: 7138043
[TBL] [Abstract][Full Text] [Related]
28. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma.
Phan TG; Cass A; Gillin A; Trew P; Fertig N; Sturgess A
J Rheumatol; 1999 Nov; 26(11):2489-92. PubMed ID: 10555916
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory morphea in the context of Raynaud phenomenon.
Abbasi N; Firoz B; Bossenbroek NM; Meehan SA; Kamino H; Franks AG
Dermatol Online J; 2008 Oct; 14(10):11. PubMed ID: 19061610
[TBL] [Abstract][Full Text] [Related]
30. Coexistence of mucosa-associated lymphoid tissue lymphoma and systemic sclerosis showing positive for anticentromere antibody and anti-RNA polymerase III antibody: A case report and published work review.
Fukumoto T; Matsuoka H; Kitani M; Sugiyama M; Fukunaga A; Nishigori C
J Dermatol; 2018 Dec; 45(12):e337-e339. PubMed ID: 29797523
[No Abstract] [Full Text] [Related]
31. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
Shah AA; Hummers LK; Casciola-Rosen L; Visvanathan K; Rosen A; Wigley FM
Arthritis Rheumatol; 2015 Apr; 67(4):1053-61. PubMed ID: 25605296
[TBL] [Abstract][Full Text] [Related]
32. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.
Faucher B; Stein P; Granel B; Weiller PJ; Disdier P; Serratrice J; Harlé JR; Durand JM; Frances Y; Guis S; Pham T; Bardin N; Sanmarco M
Eur J Intern Med; 2010 Apr; 21(2):114-7. PubMed ID: 20206882
[TBL] [Abstract][Full Text] [Related]
33. Cellular infiltrates in scleroderma skin.
Fleischmajer R; Perlish JS; Reeves JR
Arthritis Rheum; 1977 May; 20(4):975-84. PubMed ID: 861067
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis.
Stern EP; Guerra SG; Chinque H; Acquaah V; González-Serna D; Ponticos M; Martin J; Ong VH; Khan K; Nihtyanova SI; Harber M; Burns A; Mayes MD; Assassi S; Fonseca C; Denton CP
J Rheumatol; 2020 Nov; 47(11):1668-1677. PubMed ID: 32173657
[TBL] [Abstract][Full Text] [Related]
35. Characterization of patients with clinical overlap of morphea and systemic sclerosis: A case series.
Chen JK; Chung L; Fiorentino DF
J Am Acad Dermatol; 2016 Jun; 74(6):1272-4. PubMed ID: 27185438
[No Abstract] [Full Text] [Related]
36. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.
Maria ATJ; Partouche L; Goulabchand R; Rivière S; Rozier P; Bourgier C; Le Quellec A; Morel J; Noël D; Guilpain P
Front Immunol; 2018; 9():3112. PubMed ID: 30687318
[TBL] [Abstract][Full Text] [Related]
37. Association of RNA polymerase III antibodies with scleroderma renal crisis.
Nguyen B; Assassi S; Arnett FC; Mayes MD
J Rheumatol; 2010 May; 37(5):1068; author reply 1069. PubMed ID: 20439528
[No Abstract] [Full Text] [Related]
38. A case of renal crisis in a Korean scleroderma patient with anti-RNA polymerase I and III antibodies.
Kang EH; Im CH; Kim SH; Chung JR; Lee EY; Kim DJ; Lee EB; Song YW
J Korean Med Sci; 2006 Dec; 21(6):1121-3. PubMed ID: 17179700
[TBL] [Abstract][Full Text] [Related]
39. [Circulating immune complexes in progressive systemic scleroderma and morphea].
Yotsumoto H; Shimokawa Y; Hisadome H; Tashiro M
Nihon Hifuka Gakkai Zasshi; 1983 May; 93(6):579-83. PubMed ID: 6620628
[No Abstract] [Full Text] [Related]
40. [Scleroderma].
Mathieu-Serra A; Giroux JM
Union Med Can; 1977 Feb; 106(2):209-16. PubMed ID: 322372
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
